9

908 Devices Inc.
NASDAQ:MASS

Watchlist Manager
908 Devices Inc.
NASDAQ:MASS
Watchlist
Price: 6.57 USD -1.2% Market Closed
Market Cap: 237.8m USD

908 Devices Inc.
Investor Relations

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. The company is headquartered in Boston, Massachusetts and currently employs 177 full-time employees. The company went IPO on 2020-12-18. The firm's Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide answers to address problems in life sciences research, bioprocessing, industrial biotechnology, forensics and adjacent markets. Its products include MX908, Rebel and ZipChip. MX908 is a handheld Mass Spec device designed for analysis of gas, liquid and solid materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. The Rebel is a desktop analyzer providing real-time information on the extracellular environment in bioprocesses. ZipChip is a plug-and-play separation platform that optimizes Mass Spec sample analysis.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 10, 2025
AI Summary
Q3 2025

Revenue: Q3 revenue was $14 million, down 4% year-over-year but up 8% sequentially. Year-to-date revenue grew 16% versus last year.

Profitability: Adjusted EBITDA loss improved to $1.8 million, the lowest in company history, and management expects to achieve positive adjusted EBITDA in Q4.

Guidance: Full-year 2025 revenue guidance of $54–56 million was reaffirmed, representing 13–17% growth, despite up to $4 million of Q4 revenue at risk from government delays.

Product Momentum: Strong demand for XplorIR (record Q3 shipments, up 30% QoQ) and early traction for the new Viper analyzer (35+ units booked for Q4).

Cost Improvements: Facility consolidation and insourcing have reduced costs, improved gross margin, and created a more scalable operation.

Government Headwinds: U.S. government shutdown has delayed some large federal orders, but management sees this as a timing issue, not lost business.

Key Financials
Revenue
$14 million
Adjusted EBITDA
-$1.8 million
Gross Profit
$7.4 million
Gross Margin
53%
Adjusted Gross Margin
58%
Operating Expenses
$23.7 million
Net Loss from Continuing Operations
$14.9 million
Handheld Product and Service Revenue
$13.2 million
OEM and Funded Partnership Revenue
$0.8 million
Recurring Revenue
$4.8 million
Cash and Marketable Securities
$112.1 million
Devices Shipped
176
Installed Base
3,512 devices
Earnings Call Recording
Other Earnings Calls

Management

Dr. Kevin J. Knopp Ph.D.
Co-Founder, CEO, President & Director
No Bio Available
Mr. Joseph H. Griffith IV
CFO & Treasurer
No Bio Available
Mr. Michael S. Turner Esq., J.D.
Chief Legal & Administrative Officer and Secretary
No Bio Available
Dr. Christopher David Brown Ph.D.
Co-Founder, Chief Product Officer & Co-Chair of Scientific Advisory Board
No Bio Available
Mr. Steve Araiza
Co-Founder
No Bio Available
Mr. Andrew Bartfay
Co-Founder & Director of Hardware Development
No Bio Available
Mr. Michael Jobin
Co-Founder & Director of Product Development
No Bio Available
Dr. Scott Miller Ph.D.
Co-Founder & Director of MS Engineering
No Bio Available
Ms. Barbara Russo
VP of Marketing & Corporate Communications
No Bio Available
Mr. Don Osmer
Vice President of Human Resources
No Bio Available

Contacts

Address
MASSACHUSETTS
Boston
645 Summer Street
Contacts
+19787294478.0
908devices.com